Austin, Texas — August 7, 2025 — Leads & Copy — Maxwell Biosciences, a global health technology company, has announced the closing of a $20 million financing round to support upcoming FDA clinical trials and advance AI-driven R&D. The funds will also expand commercialization into industries such as cosmetics, cleaning sprays, and coatings.
According to Maxwell Biosciences Founder, CEO & Chairman Scotch McClure, the funding will allow the company to transition from deep R&D into real-world application with partners, while finalizing preparations for FDA clinical trials of Claromer drug candidates.
Claromers are synthetic small molecules that mimic the human innate immune system to target and destroy viruses, bacteria, fungi, and biofilms without harming healthy tissue. Human clinical trials are planned for 2026.
Maxwell Biosciences is collaborating with multiple governments and commercial partners to bring Claromer-based solutions to market, beginning with anti-aging cosmetics additives and molecules that target pathogenic bacteria and fungi.
Maxwell Biosciences’ COO, Head of R&D, Edward M. Rudnic, Ph.D., stated that the funding will help the company move toward human trials and commercial deployment. He also stated the data shows activity against infectious pathogens while preserving microbiome health and host cells.
Contacts:
Media: press@maxwellbiosciences.com
Investors: investor.relations@maxwellbiosciences.com
Source: Maxwell Biosciences
